Related Experiment Video
Updated: Jul 12, 2026
Clinical Protocol of Producing Adipose Tissue-Derived Stromal Vascular Fraction for Potential Cartilage Regeneration
Published on: September 29, 2018
Efficacy of Intra-articular Growth Factor Concentrate in Knee Osteoarthritis: A Randomized Controlled Trial
Sahil Shah1, Sanjeev Chincholi1, Amit Saraf1
1Department of Orthopedics, Teerthanker Mahaveer Medical College and Research Centre, Moradabad, Uttar Pradesh, India.
Introduction:
Knee osteoarthritis (KOA) is a leading global cause of pain and functional impairment, with a high prevalence in India driven by aging and obesity. Traditional treatments often provide only symptomatic relief without addressing underlying structural degeneration. This study evaluates the efficacy of intra-articular growth factor concentrate (GFC) as a regenerative and disease-modifying therapy for moderate KOA.
Materials And Methods:
In this randomized controlled trial, 72 patients with Kellgren-Lawrence (KL) Grade II or III KOA were randomized into two groups. Group A (n = 36) received two ultrasound-guided intra-articular injections of autologous GFC spaced four weeks apart, while Group B (n = 36) received normal saline. Clinical outcomes were assessed using the Visual Analog Scale (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Structural and biochemical changes were monitored via magnetic resonance imaging (MRI) (Whole-Organ Magnetic Resonance Imaging Score) and serum Coll2-1NO2 levels at baseline, 6 months, and 9 months.
Results:
A total of 66 patients completed the 9-month follow-up. Group A demonstrated a significant reduction in mean VAS scores (6.48-2.79; P < 0.0001) and WOMAC scores (62.58-47.40; P < 0.0001), indicating superior pain relief and functional improvement compared to Group B, which showed mild worsening. Biochemically, Group A showed a significant decrease in serum Coll2-1 levels (P = 0.03), suggesting reduced cartilage breakdown. MRI analysis revealed increased WORM scores in Group A (130.03-136.91; P = 0.03), indicating cartilage preservation and potential regeneration, whereas Group B scores decreased (P = 0.027).
Conclusion:
Intra-articular GFC injection is a safe and effective intervention for KL Grade II and III KOA. It provides sustained symptomatic relief and demonstrates potential disease-modifying effects through cartilage preservation and reduced degradation biomarkers. GFC represents a viable biological therapy to bridge the gap between conservative management and invasive surgical procedures.